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One of the major causes of morbidity in patients with acute 
myocardial infarction is stroke (I 2). Bn the prethrombolytic 
era, the dominant form of stroke was a bland infarct arising 
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from thromboembohc disease, often in patients with atrial 
arrhythmias or a large anterior wall infarction, or both (t-3). 
ore recently (4, intracranial hemorrhage has emerged as 
an infrequent but catastrophic complication of acute infarc- 
tion treated with thrombo~ytic therapy. 
To date, few studies have examined in detail the inci- 
dence, clinical correlates and outcomes of stroke in patients 
with acute myocardial infarction treated with t~rombolyt~c 
therapy. ltn recent large randomized trials of thrombolytic 
, the total stroke rate has ranged 
rate of i~tracra~~a~ hemo~rb~g 
routinely use computed tomographic scannirrg in stroke 
patients, making the distinction betw be~~~)rr~agic and 
nonhcmorrhag~c stroke 
that clearly emerges from the randomized trial data is that 
strokes of both types continue to occur in patients with acute 
myocardial infarctkn despite careful pretherapy screening 
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lower doses of fibrin-specific drug and a more conservative 
approach to concomitant antiplatelet therapy. The Throm- 
bolysis in Myocardial Infarction (TIMI) Phase 11 trial (10) 
carefully screened for standard risk factors and withheld 
aspirin for 48 h after recombinant tissue-type plasminogen 
activator @t-PA) therapy, but still reported a 0.5% incidence 
of intracranial hemorrhage (documented by computed tomo- 
graphic scans). 
Although standard pretherapy screening may eliminate 
the patients at highest risk for intracranial hemorrhage (for 
example, those with severe hypertension or intracranial 
tumor), there may be other risk factors for stroke or intra- 
cranial hemorrhage that, if recognized, would allow the 
clinician to improve the riskibenefit ratio of this therapy. The 
purposes of this study were I) to describe the incidence of 
hemorrhagic and nonhemorrhagic stroke in a large consec- 
utive series of patien!s with acute myocardial infarction 
treated with aggressive reperfusion therapy and 2) to exam- 
ine the clinical correlates and in-hospital and long-term 
outcomes of these patients. 
patients, the dose was I mglkg body wc~~~t for L st hour 
(maximum 90 mg), with the ~en~ai~~ng dose divided over a 
5 h infusion for a total dose of 150 . In all patients, 10% of 
the 1st hour’s dose was administe s an intravenous boius 
injection over 6 min. In the TAM1 II trial (121, 146 patients 
received combination therapy with rt-PA and low molectilar 
weight urokinase. The first 34 patients received 25 
r&PA in additive to ~ro~~~~sc (14 patients received 0.5 
million U of urokinase and 20 patients received I rn~~~io~ 
of urokinase). The remaini 1 I2 patients received I mgl 
of rt-PA in addition to urok 
U in 24 patients, I mill 
35 paticats). In the T 
rgently to the i~ter~er~tion~~~ catheterization 
re diagnostic cardiac catheteriza 
er arterial access was obtained~ 5, 
intravenous heparin was inistered. The fl 
grade 0 or i flow) underwent e 
Study patients. From December 1985 to June 1987, 708 
patients were enrolled in the Thrombolysis and Angioplasty 
in Myocardial Infarction (TAM11 I, II and Ill trials evaluat- 
ing various reperfusion strategies in acute myocardial infarc- 
tion. The entry and exclusion criteria for these three trials 
were the same and have been described in detail previously 
(I l-13). In brief, entry criteria included clinical evidence of 
an acute myocardial infarction within 4 to 6 h of symptom 
onset and electrocardiographic (ECG) evidence of epicardial 
injury. 
emergency angioplasty received an additional 5 
heparin. If residual thrombus persisted after an 
patients were eligible to receive intracoronary rt-PA (30 mg) 
or intracoronary urokinase (300 
Patients were excluded from the study if they were >75 
years of age, had previous coronary bypass surgery, were in 
cardiogenic shock at presentation or had an advanced life- 
limiting illness (for example, terminal cancer). In addition, 
particular emphasis was placed on excluding patients who 
had any of the following potential risk factors for hemor- 
rhage: I)?auma or major surgery (head, thoracic, abdominal 
or orthopedic) within 3 months: 2) severe. bleeding diathesis; 
3) prolonged cardiopulmonary resuscitation I >I0 min) 
within 2 weeks before admission: 4) gastrointestinal or 
genitourinary bleeding (within I month); 5) uncontrollled 
hypertension (diastolic blood pressure > I20 mm Hg on three 
consecutive measurements); 6) known structural intracranial 
lesions (for example, tumor or arteriovenous malformation); 
and 7) stroke, reversible ischemic neurologic deficit or 
transient ischemic attack within the previous 6 months. 
Coronary care. Patients rece a standardized medical 
regimen after leaving the catheter~~~tio~ laboratory, which 
included intravenou Sidocaine for 24 h, 325 mg of enteric- 
coated aspirin daily, iltiazem 60 mg every 6 h for 7 days and 
a constant infusion of intravenous heparin for t to 7 days. 
The heparin dose was adjusted to maintain an activated 
partial thromboplastin time at I.5 to 2.5 times the control 
value. Management of the heparin infusion after throm- 
bolytic therapy was specified in the TAM1 protocols and was 
reviewed in detail with each investigator, but specific values 
of the activated partial thromboplastin time during the infu- 
sion were not collected in the TAM1 data base. Late revas- 
cularization procedures, including coronary angiopiasty and 
coronary artery bypass grafting, were used at the discretion 
of the patient’s private cardiologist. At 5 to IO days after 
enrollment, repeat diagnostic catheterization was per- 
formed. 
Thrombolytic therapy. As previoc, ._$ described (1 l-13), 
study patients were treated with single chain &PA, In the 
~~nrologie assessment and care. Patients were examined 
TAM1 I trial !II), the first 178 patients received 60 mg of 
at least daily and any cba~~e in ~e~r~~Q~ic status WLS 
t+PA during the 1st hour, 20 mg/h during the 2nd and 3rd 
promptly evaluated by the attending physician and a neurol- 
hours and IO mg for eac5 of ?he last 5 h. in the remaiaiiag TO8 
ogist. An emergency cosrl?crted tomographic scan of t!re 
head was obtained when new neuroioglc findings were 
on the initiah 3can. 
transferred to rehabi~ita~~o~ facilities 
status was stabilized. 
e patimts had ~1 &Me 
by a ~1~~4~~~~~i~t. Str 
sudden onsci of a persistent neurologic deficit, usually focal. 
A stroke was classified as bcmor~~~agic if there was evi 
of intracranial hemorrhage on the computed tomog 
scan of the bead (Fig. I). Other strokes were classified as 
ooohemQrrtlagic. A transient ischemic attack was defined as 
a reversible neurologic deficit (~24 h) without evidence of 
checked by an ini *lendent study monitor. 
medical records of all stroke cases were reviewed by the 
neurologist coinvestigator (E.W.MJ for this study. 
Continuous data were summarized by the median and 
rhagic stroke group. A 
Fewer patients with hemo 
medications but more use 
of patients with a ~emorrbagic stroke. 
with a hemorrhagic stroke tended to have single vessef 
coronary arterv disease, whereas those w&h a ~~onberno?. 
rhagic stroke tended to have multivessel dhease (‘fable 3). 
536 O’CONNOR ET AL. 
STROKE AND HEART AITACK IN THE THROMBOLYTIC ERA 
JACC Vol. 16. No. 3 
September 199&533-40 
Table 2. Clinical Characteristics a! Presentation* 
Hemorrhagic Nonhemorrhagic No Stroke 
Stroke Group Stroke Group Group 
tn = 4) (n = 9) (n = 695) 
Mean (range1 tyr! age 68 (60-74) 65 155-68) 56 (48-64) 
Men (s/o) 25 56 80 
Weight (kg) 73 (59-82) 72 t63-83) 81 (72~9!!) 
Time from thrombolytic therapy to stroke (h) 6 (3-12) 72 t48-IOOt 
Risk factors (c/o) 
Hypertension 25 67 41 
Diabetes 25 33 I5 
Hyperlipidemia 0 22 II 
History of smoking 75 56 23 
Previous MI !%I 0 40 I2 
Physical examination 
Carotid bruit (%o) 0 0 ! 
Systolic BP (mm Hgt 130 tizu-141) E50 (I?Y-177) 130 !I 14-150) 
Diastolic BP (mm Hgt 80 (80-95) 94 (74-108) a3 (70-92) 
Abnormal neurologic examination (r/n) 0 0 I 
Home medications (%I 
None 2s II 42 
Beta-blocker 0 44 13 
Calcium channel blocker 0 II 8 
Aspirin 50 33 I9 
Dipyridamole (Persantinet 0 0 3 
Warfarin (Coumadin) 0 0 0.4 
*Continuous variables displayed as median values (25th to 75th percentile). BP = blood pressure: MI = myocar&l 
ir&ction: % = percent of patients in each group. 
The distribution of the baseline ejection fraction in the 
nonhemorrhagic stroke group was substantially lower than 
that in the hemorrhagic stroke group or the patients without 
Table 3. Baseline Coronary Angiographic Findings 
Hemorrheic 
Stroke Nonhemorrhagic No Stroke 
Group Stroke Group Group 
tn = 4tL (n = 9) In = 695) 
No. of diseased vessels (%I 
O-I 75 33 64 
2 0 22 23 
3 0 44 I3 
Infarct-related artery (k) 
Left anterior 0 78 39 
descending 
Left circumffex 50 22 I3 
Right 25 0 48 
Bypass graft 0 0 0.4 
MI location (%/c) 
Anterior 25 78 41 
Inferior 75 22 59 
Ejection fraction (%)t 62 (40~64) 36 (30-41) 53 w-591 
Acute angioplasty 0 56 43 
performed !I) 
*One patient was unable to undergo cardiac catheterization. *Data 
displayed as median values (25th IO 75th percentile). MI = myocardial 
infarction. % = percent of patients in each group. 
stroke. No patient with a hemorrhagic stroke had undergone 
acute coronary angioplasty compared with 56% of those with 
a nonhemorrhagic stroke and 43% of those with no stroke. 
Patients with a hemorrhagic stroke tended to have the 
lowest nadir fibrinogen levels, but the incidence of major 
bleeding episodes (requiring transfu-ion of r2 U of blood) 
was similar for all three patient groups (Table 4). 
~eu~o~og~c findings” The neurologic and tomographic 
findings of the head in 13 stroke patients are shown in Table 
5. Depressed mental status was much more common after 
hemorrhagic stroke than after nonhemorrhagic stroke. All 
Table 4. Laboratory Data* 
Hemorrhagic 
Stroke Nonhemorrhagic No Stroke 
Group Stroke Group Group 
(n = ~‘2 tn = 91 !n = 695) 
I”. _I 
Hematocrit (nadir) !%I 37 129-42) 28 (22-32) 32 (28-36) 
Platelet count (nadir) 232 (145-319) I60 t79-260) 187 (147-235) 
(X lO’/liler) 
Fibrinogen (nadir) 50 ( 18-76) 86 (51-l 13) 120 (51-170) 
!gldl) 
Major bleeding 25 33 I9 
(transfusion of 
=2 !J of blood) !%) 
*Continuous variables displayed as median values (25th to 75th percen- 
tile). % = percent of patients in each group. 
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aracterislics of I? Palienls 
Neurologic exam~nalio~ (%,) 
~i~bl-sided weakness 
Left-sided weakness 
Aphasia 
Depressed mental status 
Seizure 
Posterior circulation symptoms 
Cl fmdiags of the head (%) 
Normal (initial) 
Small lesion (<I ~0~~) 
Large lesion (z I cm’) 
Anlerior distribution 
Posterior distribution 
Edema 
Midline shifi 
44 
22 
33 
33 
22 
22 
0 
CT = computed ~orn~~~ap~~c~ % = percent of patients in each group. 
with bemQrrha~~c st 
gic stroke. In 75% of 
rrhagic stroke in pati 
, three c~a~cterist~cs 
no stroke gloams (0% versus 
ease was absent in the non- 
hemorrhagic stroke group but was present in 3% of the no 
stroke group. However, anterior myocard~a~ infarction with 
an ejection fraction ~45% occurred in 75% of the nonhem- 
orrhagic stroke group compared with 18% of the no stroke 
group. Of these three clinical cllaracteristics, only anterior 
Tabte 6. Prediction of Nonhemorrhagic Stroke: Logistic 
Regressnon A alvsis of Three Prespecified Independent Variables 
Variable Chl-Square p Value 
Atrial fibrillation 0.06 0.80 
Cerebrovascular disease 0.34 0.56 
Anterior myocardial infarction 10.43 0.001 
and EF ~45% 
EF = ejection fraction. 
Hemorrhagic No 
Stroke Nonhemorrhagic Stroke 
Group Stroke Group Group 
(il = 4, (ll = 9) (n = 695) 
In-hospital death (%I 25 II 6 
1 year death (%)* 0 25 3 
Nonfalal Ml (r/r )I: 0 0 6 
cdian hospilal 14 (12-51) 14 (1 I-30) 9 U-11) 
days? 
Neurologic deficit at 
discharge (%I* 
None 0 0 IOU 
Mild 33 75 0 
Severe 67 2s 0 
o&al survivors; tdata displayed as median values (251h to 35th 
percentile). Ml = myocardial infarction; % = perceni of patients in each 
group. 
tients with intracranial 
ospital death rate in 
pared with 9 days in the no stroke group. The neurologic 
deficit present at discharge in hospital survivors was severe 
enough to require further rehabilitation in 67% cif the hem- 
orrhagic stroke group compared with 25% of the nonhemor- 
rhagic stroke group. 
emorrhage is the major complication of modern throm- 
bolytic therapy and intracranial hemorrhage is the most 
astrophic form of hemorrhage seen with these th 
ytic agents. This study demonstrates that ~o~be 
rhagic stroke remains t ost common form ef stroke seen 
in patients with acut cardial infarction treated with 
thrombolytic therapy a that a large anterior myocardial 
infarction remains the major clinical correlate of this for 
stroke. However, hemorrhagic stroke has emerge 
important but unpredictable comphl-.aticin that often has 
catastrophic consequences. 
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Incidence ofstroke. In the prethrombolytic era, approxi- 
mately 3% of patients with acute myo<ardial nfarction 
developed B Stroke either concurrently with the infarction or 
during the same hospitalization (1,2). Recent randomized 
clinical trials (5-10) have demonstrated hat he stroke rate in 
patients reated with thrombolytic herapy is1% to 2% and is 
unchanged from that seen with conventional treatment. 
However, caution must be used when comparing the figures 
from current rials with the data from the prethrombolytic 
era because many patients at high risk for embolic stroke are 
excluded from treatment with thrombolytic herapy. Despite 
this important caveat, the available r sults uggest that the 
risk of embolic stroke may be reduced after thrombolytic 
therapy, perhaps because of a reduction in infarct size and 
the prevention ofclot formation i  the left ventricle asspci- 
ated with this therapy (22). This benefit is offset o shine 
extent, however, by the increase in the risk of hemorrhagic 
stroke compared with conservative treatment (8,22). 
Some controversy has arisen about the rate of stroke 
associated with different thrombolytic agents. Direct com- 
parisons of available trials have been hampered by differ- 
ences in the methods of data collection, quality control and 
dosages used. The reported stroke rates in the large “sim- 
ple” clinical trials have consistently been lower than the 
rates reported in smaller trials with detailed ata collection 
and access to rapid use of computed tomographic s ans of 
the head. Accurate classification f an individual stroke as 
hemorrhagic or nonhemorrhagic requires computed omo- 
graphic scanning. 
In the TIM1 Phase II trial (IO), patients treated with 
150 mg rt-PA had an intracranial hemorrhage rate of >I%; 
however, the 100 mg dose was associated with a risk of 
intracranial hemorrhage of 0.5%. We did not find an in- 
creased risk of stroke when rt-PA was used in combination 
with urokinase at doses lower than those r commended for
monotherapy (Table 1). 
Predictors of stroke. Most trials during the thrombolytic 
era did not examine specific linical factors associated with 
stroke. In the prethrombolytic era, stroke was sssociatec! 
with a large anterior myocardial infarction, atrial arrhythmia 
and prior cerebrovascular disease (l-3). Most of these 
events were thought to be embolic and the remainder were 
attributed to thrombotic events, hypotension and, rarely 
(<O.l%), intracranial hemorrhage. The association i this 
study between a large anterior myocardial infarction and 
nonhemorrhagic stroke is consistent with previous reports 
(l,2). In this analysis, eight of nine patients with nonhemor- 
rhagic stroke were believed by the consulting neurologist to
have an embolic stroke. 
Although some trends were evident, we could not identify 
risk fRctors for hemorrhagic stroke that would be helpful in 
excluding patients from treatment with thrombolytic ther- 
aPY. Importantly, patients with the standard major contrain- 
dications to thrombolytic therapy were already excluded 
from the three trials reviewed in this study. Althouse t al. 
(23) reported that patients with an initial elevation of drash 
tolic blood pressure had an increase in intracranial hernor- 
rhage when treated with rt-PA. Other investigators (3, 
have postulated that systemic disease leading to loss 
vascular integrity, such as diabetes or prior hypertension, 
would increase the risk of intracranial hemorrhage. In addi- 
tion, concern about he possible ffect of aspirin on hemor- 
rhagic stroke l d the TIM1 investigators (110) to withhol 
aspirin for 48 h after thrombolytic therapy was initiated. 
We attempted to use these sitnpie clinical factors to 
identify patients at increased risk of intracranial ble 
Unfortunately, these characteristics did not distinguis 
risk from low risk patients accurately enough to be us 
clinical decision making. In fact, the initial systolic and 
diastolic blood pressures were lower in the hemorrhagic 
stroke than in the nonhemorrhagic stroke group and were 
only marginally higher than in the group without stroke. 
Patients with diabetes mellitus had no increased risk of 
hemorrhagic stroke and prior use of aspirin was not associ- 
ated with an increased risk. 
Patients in this study were screened with use of a careful 
medical history to ensure that no cerebral ischemic event 
bad occurred in the preceding 6 months. The absence of a 
stroke among the 18 patients with prior cerebrovascular 
disease >6 months before treatment raises the question of 
whether patients with a remote history of stroke or transient 
ischemic attacks hould be excluded from receiving throm- 
his event rate of 0% has a 95% upper 
confidence limit of 16%. however, so these results houl 
not be regarded as definitive. 
In our exploratory analysis, several characteristics were 
more frequent in patients with hemorrhagic stroke. Women 
may have been atgreater risk because of the fixed dose of 
rt-PA used in most of these studies. We previously (24) 
demonstrated hat women, probably because of their smaller 
size, have a higher &PA concentration during the infusion 
phase, leading to more fibrinogenolysis and possibly a 
greater risk of lysis of hemostatic plugs. Older patients may 
have more defects in cerebrovascular integrity. Previous 
studies from our group (24) and others (25) found age to be 
an independent risk factor for general bleeding complica- 
tions after thrombolyt ic therapy. However, the Second 
International Study of Infarct Survival (lS~§-2) (7) has 
recently demonstrated a markedly beneficial effect of throm- 
bolytic therapy on the overall mortality rate, even in the very 
old. The absence ofprior use of a beta-adrenergic or calcium 
channel blocker in patients with stroke suggests hat these 
agents may be protective against hemorrhagic stroke by 
lowering blood pressure, reducing the rate of rise of systolic 
pressure or preventing catecholamine-induced sud en hy- 
pertension, thereby lessening the disruption of hemostatic 
plugs. 
The TIM1 II investigators observed an intracranial hem- 
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edema. 
The clinical syndr 
therapy should also be reevaluated. A co 
graphic scan should be obtained immediately. 
evacuation may be indicated on rare occasions, depending 
on iocation of the bleeding. 
e study. Two important limitations of 
dy should be noted. First, despite a large overall 
up, we only observed four hemorrhagic and nine 
nonhemorrhagic strokes. Thus, our statistical p 
detecting clinical associations is limiied. Second, t 
does not include any conservatively treated 
comparkons :vith previous experience should b 
with appropriate caution. 
Conclusions. The use of thrombolytic therapy in patients 
with acute myocardial infarction is associated with a small 
risk of stroke. A large anterior myocardial iRfarctio~ with a 
depressed left ventricular ejection fraction conti 
the major risk factor for a ~Q~hemorrhagic stroke 
patients at increased risk for hemorrhagic stroke cannot be 
detected by clinical characteristics alone with enough ACCU- 
racy to alter patient selection criteria once the standard 
exclusion criteria have been applied. The clinical course of 
both types of stroke is characterized by substantial morbid- 
ity and mortality. 
We i&be ~~ib8d~?l 10 Renee Story and Alexandria Lubans for assistance with Ihe 
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